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Methods: A total of 207 participants were offered a 25-item survey. They were asked if they wished
to know their apolipoprotein E (APOE) and amyloid PET status and if so, reasons for wanting to
know, or not, and the effects of such information on life plans.
Results: One hundred sixty-four (79.2%) of the registrants completed the survey. Among those who
were unaware of their APOE or amyloid PET results, 80% desired to know this information. The most
common reasons for wanting disclosure were to participate in research, arrange personal affairs, pre-
pare family for illness, and move life plans closer into the future.When asked if disclosure would help
with making plans to end one’s life when starting to lose their memory, 12.7% versus 11.5%
responded yes for APOE and amyloid PET disclosures, respectively. Disclosure of these test results,
if required for participation in a clinical trial, would make 15% of the people less likely to participate.
Likelihood of participation in prevention research and the desire to know test results were not related
to scores on brief tests of knowledge about the tests.
Discussion: These results suggest that stakeholders in AD prevention research generally wish to
know biological test information about their risk for developing AD to assist in making life plans.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer; Prevention; Amyloid; PET; Apolipoprotein E; Survey; Clinical trials1. Background
Owing to the advent of potentially disease-modifying
drugs that are now in clinical trials for Alzheimer’s disease
(AD), there is great interest in identifying those in the pro-
dromal [1] or preclinical [2] stage of the illness who may
benefit most from such interventions. Identification of the
most appropriate and willing subjects for these trials requiresse no conflicts of interest related to this work.
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commons.org/licenses/by-nc-nd/4.0/).large outreach programs and prescreening activities by
research sites. Family members of those afflicted with AD
are among the largest segment of stakeholders who are
most interested in possibly participating in these trials.
To accomplish the major task of identifying potential par-
ticipants for prevention trials from the population, a number
of centers have established registries, either using large scale
web-based outreach, such as the Alzheimer’s Prevention
Initiative based in Arizona [3,4], or more localized
community efforts, such as the Alzheimer’s Disease
Prevention Registry at Duke University [5] and the Wiscon-
sin Registry for Alzheimer’s Prevention [6].
Selection of prevention trial participants from such regis-
tries then rely on risk stratification. Diagnostic biomarkerimer’s Association. This is an open access article under the CC BY-NC-ND
B.R. Ott et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 23-2924tests, such as amyloid positron emission tomography (PET)
imaging, and genetic risk factor tests for apolipoprotein E
(APOE) genotype offer a means of reliably identifying peo-
ple at significant risk of developing Alzheimer’s disease, but
it is unclear how potential and already enrolled research par-
ticipants feel about their use if and when they personally
learn of the results [7,8]. Furthermore, ethical concerns
have been raised [9], including enablement for pre-
emptive suicide when people learn of risk information while
they are still cognitively intact enough to make such plans
[10]. On the other hand, there is also the potential benefit
that learning about risk for the disease will motivate individ-
uals to make important lifestyle changes to reduce risk.
Therefore, we carried out a survey of people in the Rhode
Island Alzheimer Prevention Registry (RIPR) aiming to
understand the viewpoints of cognitively intact people if
given the opportunity to learn their APOE genetic status
and amyloid PET status in a research setting. Although pre-
vious surveys have begun to address these topics in more
general samples, our study examined individuals who were
specifically interested in participating in prevention research
and who had high rates of concern about developing Alz-
heimer’s disease or dementia.2. Methods
RIPR was established in 2012 with the support of an
infrastructure grant under the Alzheimer’s Disease Cooper-
ative Study with the goal of enlisting people in the commu-
nity with normal cognitive and daily living function who are
interested in participating in Alzheimer prevention research.
The RIPR is included in the Rhode Island State Plan for Alz-
heimer’s Disease [11] that was instituted in response to the
National Plan to Address Alzheimer’s Disease [12]. Partici-
pants are recruited by various community outreach efforts
such as public presentations and advertisements as well as
directly from the family and friends of patients attending
the Rhode Island Hospital Alzheimer’s Disease andMemory
Disorders Center, a large hospital-based tertiary diagnostic
and treatment center that receives referrals from the south-
eastern New England area.
Participants are invited to come for an office visit, for
cognitive and APOE genetic testing, but this office visit is
not required. Of the people who have enlisted in the RIPR,
90.2% have completed the office visit to date, with the
remainder yet to be scheduled or refused due to inconve-
nience on the part of the participant. All participants sign
an informed consent approved by the Rhode Island Hospital
Institutional Review Board. All participants are interviewed
by phone, and basic demographic information is collected as
well as information on exercise, diet, and family history of
dementia. Medical and psychiatric history and medication
usage data are collected as well. Exclusion criteria include
diagnosis of Alzheimer’s disease or any dementia disorder,
diagnosis of a major psychiatric condition that could
impair cognition, including alcoholism by Diagnostic andStatistical Manual of Mental Disorders, 4th Edition criteria,
diagnosis of mental retardation, Down’s syndrome, or other
major learning disability, education ,6 years, non-English
speaking, other neurologic disorder that affects cognitive
(e.g., traumatic brain injury, stroke, Parkinson’s disease),
and age ,45 years.
TheMinnesota Cognitive Acuity Screen (MCAS) [13] is a
cognitive screening instrument administered by phone to
further exclude those likely to have dementia. Those in the
range of mild cognitive impairment on this scale are not
excluded. The MCAS has been shown to have good discrim-
ination function between AD, mild cognitive impairment
(MCI), and normal subjects [14,15] when used by
telephone, and it has also been shown to have predictive
ability for functional decline and conversion to dementia in
one longitudinal study [16]. Among current registry partici-
pants, 16.7% are classified asMCI and the rest as being cogni-
tively normal, using established cutoff scores for the MCAS.
The 207 people enrolled in the registry as of October
2014 were offered an anonymous 25-item survey to com-
plete on paper or online. No standard educational materials
were provided to participants before completing the survey.
Questions were asked about whether participants knew or
wished to know their APOE genetic status and amyloid
PET status and if so, their reasons for wanting to know, or
not, and the effects of such information on their beliefs
and life plans.
Other questions assessed demographic items as well as
their knowledge about APOE and amyloid PET. Knowledge
questions about APOE status included these true or false
statements about APOE: (1) Is a genetic risk factor for Alz-
heimer’s disease. If you have this risk factor, you will defi-
nitely get Alzheimer’s disease if you live long enough; (2)
Is a genetic risk factor. If you have this risk factor, you are
more likely to get Alzheimer’s disease than those who do
not; (3) Has not yet been established to be a risk factor for
developing Alzheimer’s disease; (4) Is commercially avail-
able; and (5) Is routinely done as part of the diagnostic eval-
uation for Alzheimer’s disease performed by most
physicians. Knowledge questions about amyloid PET
included these true or false statements about APOE: (1) Is
a brain imaging test that is used to diagnose dementia; (2)
Is a brain imaging test that can be used to help rule out or
exclude Alzheimer’s disease as the cause of dementia; (3)
Is a brain imaging test that can reliably demonstrate if there
are significant amounts of amyloid plaques in the brain; (4) If
showing no amyloid in the brain, means you will not develop
Alzheimer’s dementia; (5) Is commercially available; and
(6) Is routinely done as part of the diagnostic evaluation
for Alzheimer’s disease performed by most physicians.
Before development of the survey questions, the medical
literature on the topics of disclosure of APOE and amyloid
PET status was reviewed by examining all articles in the
English language from a search of PubMed over 10 years
plus meeting abstracts during the past year. For sake of com-
parison, questions regarding reasons for wanting to know
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REVEAL study [17]. The final questions chosen for the sur-
vey, including their exact wording, were derived from
consensus of the authors.
One hundred sixty-four people completed the survey
(response rate 79.2%); 138 completed the survey by mail
and 26 completed it online. Demographic characteristics
of the respondents are presented in Table 1.3. Results
Participants who felt they had memory problems worse
than other individuals of the same age they knew were
27.5%, and of these, 72.9% were concerned about the mem-
ory changes. Participants who felt it was unlikely that they
had AD were 8.6%, whereas 26.5% felt they probably had
AD. Self ratings of mood were happy all the time (32.7%),
occasional feelings of depression (60.5%), depressed most
days (6.2%), and severely depressed (.6%).
Respondents were asked five questions to test their
knowledge about the APOE test and six questions to test
their knowledge about amyloid PET. The proportions of cor-Table 1
Demographic characteristics of survey sample (n 5 164)
Characteristics
Age (SD)
Race (%)
Gender (% female)
Education (%)
Estimated annual income (%)
Family history of Alzheimer’s or dementia (%)
Caregiver for family member (%)
You have memory problems worse than others your age that you know (%)
Others have expressed concern about your memory (%)
On a scale of 0 to 100, rate your risk of developing AD (SD)
Rate your risk of developing AD (%)
Rate your mood (%)
Rate your anxiety and worries
Abbreviations: SD, standard deviation; AD, Alzheimer’s disease.rect response for each category of test are shown in Fig. 1.
Over 70% of respondents were able to answer at least four
questions correctly.
Ten had received disclosure of their APOE status and 13
had received disclosure of their amyloid PET status. Among
those participants who knew their genetic risk or PET status,
none reported feeling depressed, suicidal, or hopeless after
receiving this information. Several of these individuals
comprise a recent multiple case report that confirms this
finding [18].
Among those who were unaware of their APOE status,
80.3% desired to know this information. Desire to know
about APOE status was associated with higher perceived
risk for developing AD (odds ratio [OR] 5 3.25; 95% con-
fidence interval [CI] 5 1.25–8.47, P 5 .002). Self-reported
memory complaints were correlated with less desire to
know their status (OR 5 0.21; 95% CI 5 0.05–0.96,
P 5 .04). The most common reasons expressed for wanting
disclosure were to participate in AD research (75.9%),
arrange personal affairs (74.1%), and move plans closer in
the future (65.5%). Among those wishing this information,
12.7% would use the information to make plans for endingFrequency
64.7 6 9.2
96.7 White
2.5 Black
0.08 Mixed
73.9
0.1 Less than high school
21.7 High school graduate
42.0 College graduate
35.7 Advanced degree
20.8 ,30,000
22.2 $30,000–$50,000
41.7 $50,000–$100,000
13.9 $100,000–$200,000
1.4 .$200,000
71.8 At least one parent
15.8 Both parents
7.6 Sibling
52.3
27.5
21.2
51.3 6 25.6
8.6 Unlikely
64.8 Possible
25.3 Probable
1.2 Certain. I think I already have it.
32.7 Happy all the time/no depression
60.5 Occasional feelings of depression
6.2 Depression most days
0.6 Severely depressed
6.8 Never anxious or worried
78.4 Occasional anxiety and worries
14.8 Anxious and worried on most days
0.0 Severely anxious
Fig. 1. Knowledge test responses. Abbreviations: APOE, apolipoprotein E;
PET, positron emission tomography.
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The most common reasons for not wanting disclosure were
concerns that they would feel anxious or depressed if they
had the risk factor gene (40%), Table 3.
Among those who were unaware of their amyloid PET
status, 80.6% desired to know this information. Demo-
graphic and psychological factors related to desire to know
their status included perceived risk of having AD
(OR 5 1.03; 95% CI 5 1.01–1.06, P 5 .001) or developing
AD (OR5 8.53; 95% CI5 2.49–29.21, P5 .001), whereas
having an affected parent was inversely related (OR5 0.29;
95% CI5 0.12–0.73, P5 .008). The most common reasons
expressed for wanting disclosure were to participate in AD
research (73.2%) and prepare spouse or children for their
illness (60.2%). Among those wishing this information,
11.5% would use the information to make plans for ending
their life when they started to lose their memory, Table 2.
The most common reason for not wanting disclosure was
feeling depressed if amyloid was elevated on PET (40%),
Table 3.
Disclosure of APOE test results, if required for participa-
tion in a clinical trial, would make 43.7% of people moreTable 2
Reasons for wanting disclosure
Reason
To participate and contribute to Alzheimer research
To arrange your personal affairs
To do things sooner than you had planned to do in the future
To prepare your spouse or children for your illness
To arrange your long-term care
To learn information for family planning
For relief that your chances are lower than you think
Curiosity/researched the finding
To confirm the feeling that you are already showing symptoms of the disease
To confirm the feeling that you are going to get the disease
To plan for ending your life when you start to lose your memory
Let it go/put it out of your mind
Abbreviations: APOE, apolipoprotein E; PET, positron emission tomography.likely to participate and 14.8% of people less likely to partic-
ipate. Disclosure of amyloid PET results, if required for
participation in a clinical trial, would make 41.6% of people
more likely to participate and 15.3% of people less likely
to participate. The likelihood of participation and the desire
to know APOE and PET results were not significantly related
to total scores on the tests of knowledge.4. Discussion
These survey results show that the vast majority of stake-
holders in AD prevention research wish to know biological
test information about their risk for AD, not only for the pur-
pose of participating in research but also to assist in making
life plans. A minority of potential participants would prefer
not to be informed due to the potential anxiety and depres-
sion that may result from having a positive test result.
Furthermore, providing such knowledge would have a
more positive than negative overall effect on recruitment.
Although stakeholders at risk for AD are clearly inter-
ested in learning more about their individual risk, even the
general population is keenly interested in knowing this infor-
mation. For example, a general population survey of 314
individuals found that 79% of respondents stated that they
would take a hypothetical genetic test to predict whether
they would eventually develop AD [19]. In a survey module
that was added to the Health and Retirement Study, among
1641 older adults, 60% indicated interest in testing that
would help them learn about their AD risk [20]. In a cross-
sectional telephone survey of 2678 adults across the United
States and four European countries, 67% reported that they
were “somewhat” or “very likely” to get a medical test to
detect early AD if one became available [21].
Other studies focusing on more clearly at-risk samples in
research settings such as ours have had similar findings. One
survey of first-degree relatives of individuals with AD [22]
examined beliefs and attitudes toward APOE predictive
testing using hypothetical situations and found that theAPOE, n 5 116
(% of respondents)
Amyloid PET, n 5 108
(% of respondents)
75.9 73.2
74.1 74.1
65.5 58.3
64.7 60.2
56.9 55.6
56.9 52.8
49.1 46.3
43.4 51.9
16.4 13.9
14.7 13.9
12.7 11.5
8.6 5.6
Table 3
Reasons for not wanting disclosure
Reason
APOE, n 5 25
(% of respondents)
Amyloid PET, n 5 25
(% of respondents)
It would frighten you or cause anxiety, if you had the risk factor gene or amyloid was elevated on PET 40.0 28.0
It would make you depressed, if you had the risk factor gene or amyloid was elevated on PET 40.0 40.0
You would not know what to do with the information 36.0 32.0
It might influence your life decisions or plans. 24.0 32.0
No interest in knowing 20.0 28.0
Abbreviations: APOE, apolipoprotein E; PET, positron emission tomography.
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late-life decisions and planning future AD care. This study,
as well as ours, also noted that perceived risk was strongly
associated with desire to obtain genetic test information,
whereas (as in the case of amyloid PET in our study) having
a family history of AD reduced the interest in getting predic-
tive testing. The reason for this latter observation as well as
the observation that self-reported memory complaints were
also related reduced interest in predictive testing is unknown
but possibly due respondents already feeling that they know
that they are at risk and are not in need of additional informa-
tion.
These results are also very similar to those obtained from
a survey performed online in 4036 people from the Alz-
heimer Prevention Registry based in Arizona [23].
Compared with our sample, respondents in this survey
were younger (age 18 vs. 45 and mean 58.0 vs.
64.7 years), more often female (82.1% vs. 73.9%), less likely
to have a first-degree relative with AD (61.3% vs..71.8%),
and more likely to be college educated (66.2% vs. 42.0%).
Despite these differences as well as the method of registry
enrollment (online vs. telephone or in person), their results
produced similar trends. Like our sample, respondent under-
standing of biomarker testing was poorer for amyloid PET
than for genetic testing (32.6% vs. 13.1%). A large majority
(70.4%) felt that presymptomatic APOE genetic testing was
important, and they would use the information for positive
reasons such as beginning a healthier lifestyle (90.5%) and
getting long-term insurance (76.3%). Similar results were
seen for PET and spinal fluid biomarker disclosure: 80.2%
of their respondents wanted to know biomarker results to
reveal AD years before symptom onset, quite consistent
with the rate of 80.6% in our sample who wished to know
their amyloid PET status. Overall, our results extend the
findings from the Arizona survey and suggest that desire to
know risk status for AD is not restricted to highly educated
and younger individuals.
Of particular concern, the Arizona survey found a minor-
ity of people who would use disclosure to “seriously
consider suicide” (11.6% for APOE and 10.2% for
biomarker disclosure). We asked a related but more specific
question applying to pre-emptive suicide and found that a
minority of respondents (12.7% for APOE and 11.5% for
amyloid PET disclosure) would use the disclosure to “planfor ending your life when you start to lose your memory.”
We agree with their conclusions that there is a need for
greater public education on genetic and biomarker tests for
AD and that psychological assessments for depression and
counseling should be part of screening those who can or
should be provided this information.
To address this concern, a standardized screening and
disclosure process for amyloid PET has been successfully
implemented in over 300 participants in the A4 secondary
prevention trial so far [24]. Longitudinal assessment of the
impact of such disclosure will be obtained in a substudy
currently being conducted by telephone interview of partic-
ipants.
Although it currently appears to be safe as well as gener-
ally acceptable or desirable for research participants in pre-
vention studies to receive risk information, the ethics of
disclosing genetic susceptibility information such as
APOE genotype is still an area of some debate. First of all,
the professional disclosing the information needs to be
cognizant of the diagnostic and prognostic implications of
the test results which imply risk but are not in themselves
deterministic. Perhaps more importantly, the ethics depend
on empirical evidence of how people actually perceive,
recall, and communicate this type of complex risk informa-
tion [9]. The conservative approach has been to withhold
such information when acquired in research studies from in-
dividuals concerned about their risk for AD for fear of gener-
ating unwarranted stress and anxiety. This paternalistic view
has been challenged, however, by results from the REVEAL
study [25], indicating that disclosure of APOE genotyping
results to a select group of adult children of patients with
AD did not result in significant short-term psychological
risks.
Although data from the REVEAL study are reassuring
with regard to APOE disclosure, there is very limited infor-
mation to date on the psychological impact on individuals
who have had disclosure of their amyloid PET status, so con-
troversy exists regarding whether such imaging information
should be disclosed in clinical and research settings [26]. In a
preliminary report from the University of Kansas Alz-
heimer’s Prevention Program Exercise trial [27], disclosure
of elevated amyloid status to 25 cognitively normal partici-
pants did not significantly increase anxiety or depression
scores at baseline or at 6 months. Furthermore, these
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and exercise. This same finding was also recently reported
for a subgroup of our own registry participants [18].
Importantly, it should be noted that disclosure of risk
information would serve to limit recruitment in only a mi-
nority of people who are interested in AD prevention
research. Indeed, disclosure would serve to enhance likeli-
hood of participation for 43% of people if givenAPOE infor-
mation and 41.6% of people if given amyloid PET
information in our sample. Similarly, knowing that one is
at 50% increased risk for AD was found in one study using
hypothetical scenarios to enhance recruitment into preclini-
cal AD trials [28]. Another recent hypothetical clinical trial
survey involving 132 cognitively normal people found that
those assigned to a risk disclosure armwere 10%more likely
to enroll than those in a nondisclosure arm. Furthermore,
96% of participants in the disclosure arm stated that they
would want to learn their amyloid PET results [29].
Although the availability of prevention trials provides a
reasonable incentive for people to undergo genetic [30] as
well as amyloid PET risk testing [29] with disclosure of sta-
tus, the fears and anxiety that a minority of people express
about being given such information, as well as the possibility
that the information could motivate suicidal ideation for
some, points to the need for vigilance about psychological
risk and efforts to minimize these risks through carefully
designed disclosure protocols, such as the one currently
being used in the A4 clinical prevention trial [24].
There are a number of limitations from this survey study
that warrant consideration. The sample was highly selected
to include only those older people who were specifically
interested in participating in AD prevention research studies,
so the results cannot be generalized to the larger population
of people who are concerned about their risk for developing
AD. In addition, limiting generalizability is the high educa-
tional status of the sample and the low number of minorities.
A less well-educated group, and a more diverse group
racially and ethnically, might have dramatically altered the
results and conclusions of this survey. Although telephone
and in-office cognitive tests were performed in registry par-
ticipants to exclude dementia, we did not have the cognitive
tests results of the respondents, so some of them likely had
MCI and were not “normal.” Reduced interest in predictive
testing among those with subjective complaints may have
been driven by those with the greatest actual impairment,
i.e., those with MCI.
Most importantly, the respondents to our survey were
addressing hypothetical questions about their potential
access to risk information. The registry does not provide
this information to participants in actual practice. Therefore,
it is unknown to what extent these viewpoints would trans-
late to actual behaviors once the respondents would have
been provided access to the information.
These data will hopefully stimulate further discussions in
research circles and among stakeholder groups. Future
research should involve a larger number of people afterthey have been informed of their amyloid PET status to pro-
vide additional insight on the effects of such knowledge on
actual behaviors and decisions. Long-term studies on behav-
ioral and psychological outcomes should be done to comple-
ment cross-sectional studies such as this one. There is also a
need to better understand the long term and the immediate
ethical issues surrounding AD risk disclosure.
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1. Systematic review: In addition to surveying stake-
holders in Alzheimer prevention research from a reg-
istry, we searched PubMed over 10 years and
meeting abstracts in the past year.
2. Interpretation: Amyloid positron emission tomogra-
phy (PET) and apolipoprotein E genotyping offer
means of identifying people at risk of developing
Alzheimer’s disease (AD), but it is unclear how
research participants feel about personal access to
such test results. Stakeholders generally wish to
know biological test information about their risk
for developing AD to assist in making life plans as
well as to decide on participation in prevention
research. In a small minority, however, those plans
may include pre-emptive suicide.
3. Future directions: Future research should involve
larger samples who have been informed of their am-
yloid PET status to provide additional insight
regarding effects on actual behaviors and decisions.
There is also a need to better understand the long
term and the immediate ethical issues surrounding
AD risk disclosure.References
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